\
&
Contact us
\
&
Contact us
Published on | 2 years ago
Programmes Enhancing EU R&IThe results of the evaluation of the EU Award for Gender Equality Champions competition with call deadline 13 October 2022 are as follows:
Number of applications submitted: 40
Number of inadmissible applications: 24
Number of ineligible applications: 0
Winners: 4
For more information on the winners please see the prize website.
For questions, please contact the Research Enquiry Service.
Source: Funding and Tender Portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Deployment: Best use of technologies
Please note that the European Commission has extended the deadline for call DIGITAL-2025-BESTUSE-TECH-09 with the following two call topics: European Digital Identity Wallet EU Mobile Driving Licences) NEW closing date: 15 January 2026 (previously 09 December 2025) read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
